WO2025087365 - METTL3 INHIBITOR
National phase entry is expected:
Publication Number
WO/2025/087365
Publication Date
01.05.2025
International Application No.
PCT/CN2024/127250
International Filing Date
25.10.2024
Title **
[English]
METTL3 INHIBITOR
[French]
INHIBITEUR DE METTL3
[Chinese]
METTL3抑制剂
Applicants **
HANGZHOU BANGSHUN PHARMACEUTICAL CO., LTD.
Inventors
WEN, Qiaodong
YANG, Xin
CUI, Rong
ZHENG, Mei
YIN, Jianming
LV, Yubin
Priority Data
202311399919.8
26.10.2023
CN
202311529351.7
16.11.2023
CN
202410091151.6
23.01.2024
CN
202410349037.9
26.03.2024
CN
202410883982.7
03.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2864 | |
| EPO | Filing, Examination, Granting | 16846 | |
| Japan | Filing, Examination, Granting | 2301 | |
| South Korea | Filing, Examination, Granting | 2507 | |
| USA | Filing, Examination, Granting | 5190 |
Total:
29,708
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed in the present invention are a METTL3 inhibitor as shown in general formula (I), a pharmaceutical composition thereof, a preparation method therefor, and the use thereof in the preparation of a drug for preventing and/or treating indications related to METTL3. The compound of the present invention is an ideal high-activity METTL3 inhibitor, and can be used for treating and/or preventing diseases, including AML, myeloid leukemia, and solid tumors such as hepatocellular carcinoma, colorectal cancer and prostate cancer.[French]
La présente invention concerne un inhibiteur de METTL3 tel que représenté dans la formule générale (I), une composition pharmaceutique de celui-ci, son procédé de préparation et son utilisation dans la préparation d'un médicament pour la prévention et/ou le traitement d'indications liées à METTL3. Le composé de la présente invention est un inhibiteur idéal de METTL3 à activité élevée, et peut être utilisé pour traiter et/ou prévenir des maladies, y compris la LMA, la leucémie myéloïde et des tumeurs solides telles que le carcinome hépatocellulaire, le cancer colorectal et le cancer de la prostate.[Chinese]
本发明公开了一种通式(I)所示的METTL3抑制剂，其药物组合物、制备方法及其在制备、预防和/或治疗与METTL3相关适应症的药物的用途。本发明的化合物是理想的高活性METTL3抑制剂，可用于治疗和/或预防的疾病，包括AML、髓性白血病、实体瘤如肝细胞癌、结直肠癌、前列腺癌。